Schwab Charles Investment Management Inc. boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 36.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 38,906 shares of the specialty pharmaceutical company’s stock after buying an additional 10,489 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.33% of ANI Pharmaceuticals worth $1,927,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ANIP. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 90.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 91,514 shares of the specialty pharmaceutical company’s stock valued at $5,548,000 after buying an additional 43,534 shares during the period. Mesirow Financial Investment Management Equity Management boosted its stake in ANI Pharmaceuticals by 99.0% in the first quarter. Mesirow Financial Investment Management Equity Management now owns 6,895 shares of the specialty pharmaceutical company’s stock valued at $341,000 after buying an additional 3,430 shares in the last quarter. Strs Ohio boosted its stake in ANI Pharmaceuticals by 29.2% in the first quarter. Strs Ohio now owns 13,700 shares of the specialty pharmaceutical company’s stock valued at $678,000 after buying an additional 3,100 shares in the last quarter. Stoneridge Investment Partners LLC bought a new stake in ANI Pharmaceuticals during the first quarter valued at about $482,000. Finally, Chicago Equity Partners LLC boosted its stake in ANI Pharmaceuticals by 5.2% in the first quarter. Chicago Equity Partners LLC now owns 17,360 shares of the specialty pharmaceutical company’s stock valued at $859,000 after buying an additional 860 shares in the last quarter. Institutional investors and hedge funds own 55.63% of the company’s stock.
ANI Pharmaceuticals, Inc. (NASDAQ ANIP) traded down 0.613% during mid-day trading on Friday, hitting $46.185. 12,884 shares of the company were exchanged. ANI Pharmaceuticals, Inc. has a 12-month low of $42.23 and a 12-month high of $69.85. The company has a market cap of $537.50 million, a price-to-earnings ratio of 101.061 and a beta of 3.08. The stock’s 50 day moving average is $46.44 and its 200-day moving average is $49.41.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The company had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.20 million. During the same period last year, the company earned $1.11 earnings per share. The firm’s revenue was up 43.0% compared to the same quarter last year. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post $3.84 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/25/schwab-charles-investment-management-inc-has-1-93-million-position-in-ani-pharmaceuticals-inc-anip.html.
Several analysts recently issued reports on the stock. Roth Capital set a $56.00 price target on shares of ANI Pharmaceuticals and gave the company a “hold” rating in a report on Saturday, May 6th. BidaskClub raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Canaccord Genuity reissued a “buy” rating and set a $60.00 target price on shares of ANI Pharmaceuticals in a report on Wednesday, August 9th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Guggenheim reissued a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, July 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $65.33.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
